Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | MANIFEST study of CPI-0610 in myelofibrosis

John Mascarenhas • 8 Dec 2019
ASH 2019
Myelofibrosis Myeloproliferative Neoplasms CPI-0610 Ruxolitinib
MANIFEST

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, presents the results of the phase 2 MANIFEST study of CPI-0610, an oral BET inhibitor, as a monotherapy or in addition to ruxolitinib, in refractory or intolerant advanced myelofibrosis. Preliminary data indicate that CPI-0610 alone or as an add-on is generally well-tolerated and provides clinical benefits, and the study is being further expanded. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from John Mascarenhas

1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
1:30
MDM2 inhibitors in myelofibrosis treatment: the addition of navtemadlin to ruxolitinib
John Mascarenhas • 10 Dec 2023
1:18
Immunotherapeutic approaches in CALR-mutated MPNs
John Mascarenhas • 9 Sep 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals